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Abstract
Background: The development of Plasmodium falciparum resistance to chloroquine (CQ) has limited its use in
many malaria endemic areas of the world. However, despite recent drug policy changes to adopt the more
effective artemisinin-based combination (ACT) in Africa and in the Southern African region, in 2007 Swaziland still
relied on CQ as first-line anti-malarial drug.
Methods: Parasite DNA was amplified from P. falciparum isolates from Swaziland collected in 1999 (thick smear
blood slides) and 2007 (filter paper blood spots). Markers of CQ and sulphadoxine-pyrimethamine (SP) resistance
were identified by probe-based qPCR and DNA sequencing.
Results: Retrospective microscopy, confirmed by PCR amplification, found that only six of 252 patients treated for
uncomplicated malaria in 2007 carried detectable P. falciparum.T h epfcrt haplotype 72C/73V/74I/75E/76T occurred
at a prevalence of 70% (n = 64) in 1999 and 83% (n = 6) in 2007. Prevalence of the pfmdr1-86N allele was 24% in
1999 and 67% in 2007. A novel substitution of phenylalanine for asparagine at codon 86 of pfmdr1 (N86F) occurred
in two of 51 isolates successfully amplified from 1999. The pfmdr1-1246Y allele was common in 1999, with a
prevalence of 49%, but was absent among isolates collected in 2007. The 86N/184F/1246D pfmdr1 haplotype,
associated with enhanced parasite survival in patients treated with artemether-lumefantrine, comprised 8% of 1999
isolates, and 67% among 2007 isolates. The pfdhfr triple-mutant 16C/51I/59R/108N/164I haplotype associated with
pyrimethamine resistance was common in both 1999 (82%, n = 34) and 2007 (50%, n = 6), as was the wild-type
431I/436S/437A/540K/581A/613A haplotype of pfdhps (100% and 93% respectively in 1999 and 2007). The
quintuple-mutant haplotype pfdhfr/pfdhps-CIRNI/ISGEAA, associated with high-level resistance to SP, was rare (9%)
among 1999 isolates and absent among 2007 isolates.
Conclusions: The prevalence of pfcrt and pfmdr1 alleles reported in this study is consistent with a parasite
population under sustained CQ drug pressure. The low prevalence of dhps-437G and dhps-540E mutations
(ISGEAA) and the rarity of quintuple-mutant haplotype pfdhfr/pfdhps-CIRNI/ISGEAA suggest that SP retains some
efficacy in Swaziland. Anti-malarial policy changes in neighbouring countries may have had an impact on the
prevalence of molecular markers of anti-malarial resistance in Swaziland, and it is hoped that this new information
will add to understanding of the regional anti-malarial resistance map.
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The emergence and spread of drug resistant malaria
poses the greatest challenge to the control and elimina-
tion of malaria in Swaziland. Despite reports of chloro-
quine failure suspected to be a result of drug resistance
in the 1980s [1], CQ has remained the first-line drug for
treatment of uncomplicated Plasmodium falciparum
malaria in Swaziland. The combination of sulphadoxine
and pyrimethamine (SP) has been an effective and
affordable alternative single dose treatment for CQ-
resistant parasites since its first introduction to Africa in
the 1960s. Use of SP increased rapidly in countries with
CQ resistance over the next 30 years. As a result, resis-
tance to SP is now globally widespread [2], leading most
malaria endemic countries in Africa to abandon SP
alone as first-line treatment. In Swaziland, SP was intro-
duced in 1993 as a second-line treatment for uncompli-
cated malaria following reports of CQ failure in
Mozambique [3-5], South Africa (KwaZulu-Natal) [6]
and Swaziland [1]. To this day, SP remains a second-
line anti-malarial in Swaziland despite its withdrawal as
a first-line anti-malarial in KwaZulu-Natal (2001) and
Mozambique (2002). Resistance to CQ is associated with
polymorphisms in the pfcrt and pfmdr1 genes, and resis-
tance to SP with pfdhfr and pfdhps polymorphisms. No
data are available concerning the diversity of these loci
in Swaziland.
The mutation at codon 76 of the pfcrt gene, where
lysine is replaced by threonine (K76T) has been strongly
associated with P. falciparum resistance to CQ and sub-
sequent treatment failure [7]. Mutations in the pfcrt
gene at codons other than K76T are said to modulate
CQ resistance and/or compensate deleterious effects of
K76T mutations [8]. Mutations in the pfmdr1 gene
(N86Y, Y184F, S1034C, N1042D and D1246Y) have
been reported to modulate the level of CQ resistance
[9-11]. Recent studies have further associated some
alleles of the pfmdr1 gene with decreased susceptibility
to artemisinin-containing drugs. Artemether-lumefan-
trine (AL) is currently the most favoured combination
therapy against uncomplicated Plasmodium falciparum
malaria in southern Africa. However, in vivo studies of
AL-treated patients have shown enhanced survival of
parasites carrying the pfmdr1 polymorphisms (86N,
184F and 1246D) and selection against the YYY haplo-
type [12,13]. Studies have also reported an increased
pfmdr1 copy number in parasites of Asian origin follow-
ing AL treatment [14]. Selection of the NFD haplotype
and increased pfmdr1 copy number could result in
reduced susceptibility of parasites to AL and further
investigation of pfmdr1 in areas implementing AL treat-
ment policy are clearly needed.
Resistance to SP has been shown to occur following
changes in the amino acid sequences of the dihydrofo-
late reductase (DHFR) [15] and dihydropteroate
synthase (DHPS) [16] enzymes, with both in vitro and
in vivo studies finding associations between mutations
in the dhfr gene of P. falciparum and resistance to pyri-
methamine [17,18] and between mutations in the pfdhps
gene and resistance to sulphadoxine [19,20]. The level
of resistance to SP has been shown to increase with
accumulation of mutations in codons 51, 59, 108 and
164 in pfdhfr and in codons 437 and 540 in pfdhps
[21,22]; the contribution to resistance of mutations at
positions 431, 436, 581 and 613 of pfdhps remains
unclear [23].
This report describes molecular screening of 79 iso-
lates from Swaziland collected in 1999 and 2007. Resis-
tance-associated polymorphisms in the pfcrt, pfmdr1,
pfdhfr and pfdhps genes were determined by multiplex
qPCR and direct DNA sequencing of conventional PCR
products.
Methods
Study samples
Two hundred and fifty-two blood samples were col-
lected from patients clinically diagnosed with uncompli-
cated malaria in eight health centres in the malaria
endemic lowveld of Swaziland between 01 February and
30 April, 2007. Only six of these patients were con-
firmed microscopy positive for P. falciparum by two
laboratory technicians working independently. Twenty-
four of the microscopy-negative samples (10%) were
randomly selected to further confirm the validity of the
laboratory confirmation by PCR. Seventy-three glass
microscope slides with Giemsa-stained thick blood
smear samples from confirmed malaria cases in 1999
were also obtained for the analysis. These came from
Simunye, on the northern lowveld of Swaziland and Big
Bend in the Ubombo Ranches on the southern lowveld
of Swaziland. The two centres attract patients from the
whole malarious region of Swaziland, with Simunye pro-
viding diagnosis and treatment for patients from the
northern part and Big Bend for patients from the south.
The study was approved by the London School of
Hygiene and Tropical Medicine Ethics Committee and
the Ministry of Health and Social Welfare (Swaziland)
Ethics Committee. Written informed consent was
obtained from all participants or parents/guardians in
the case of children.
Isolation of DNA
Parasite genomic DNA was extracted from dried filter
papers using the Chelex®100 method according to
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lysed in 5% saponin in 1 × PBS and incubated at 37°C
overnight. The samples were centrifuged, saponin and
debris were removed using a vacuum pump, and the pel-
lets washed twice in buffered saline. The samples were
then suspended in 6% Chelex®100 resin and heat-sealed in
deep 96-well plates. The samples were incubated in boiling
water for 20 - 25 minutes and then centrifuged to remove
resin. Approximately 100 μl of supernatant containing
DNA was removed and stored at -20°C.
Parasite DNA was isolated from stained thick blood
smears using the QIAmp Mini Blood Purification kit
(QIAGEN, UK) following the manufacturer’si n s t r u c -
tions. A sterile scalpel was used to spread lysis buffer
over the blood and to scrape material into a 1.5 ml
microcentrifuge tube for further processing. The DNA
was finally collected in 100 μl of elution buffer, centri-
fuged at 8 000 g for 1 min and stored at -20°C.
Parasite genotyping by PCR
pfcrt
The genotype of the pfcrt gene for polymorphisms C72S,
M74I, N75E, and K76T was determined in at least two
multiplex real-time qPCR runs with full agreement
using the Rotorgene 3000 platform (Corbett Research,
Australia). Primer sets and cycling conditions were as
described previously [25], in the presence of the double-
labelled probes representing CVIET, CVMNK and
SVMNT haplotypes. 3D7, Dd2 and 7G8 DNA obtained
from the Malaria Research & Reference Reagent
Resource (MR4, Manassas, Vermont, USA) was used to
provide sequence-specific positive controls and nucle-
ase-free water was included as a negative control.
pfmdr1
Amplification of the pfmdr1 gene was initially per-
formed in two fragments (FR1 and FR2). Primers and
cycling conditions used for FR1 and FR2 are described
elsewhere [13]. For some samples, FR2 amplification
was unsuccessful, and so two smaller fragments, FR3
and FR4, encompassing the codons of interest in FR2,
were amplified. Primers and cycling conditions for FR3
and FR4 are listed in Table 1.
pfdhfr and pfdhps
Amplification of pfdhfr and pfdhps genes involved pri-
mers and cycling conditions described elsewhere [23,26].
All amplicons of the pfmdr1, pfdhfr and pfdhps genes
were re-amplified in a nested PCR step. The PCR pro-
ducts of nested reactions were separated by gel electro-
phoresis on a 1.2% agarose gel stained with ethidium
bromide to identify amplified bands of DNA under
ultra-violet illumination. Amplicons from nested PCR
reactions were purified using the QIAquick PCR Purifi-
cation Kit (QIAGEN, UK) according to manufacturer’s
instructions and subjected to di-deoxy fluorescent
sequencing (BigDye 3.1, Applied Biosystems, UK) using
conditions and sequencing primer pairs described else-
where [13,25,26] or as shown in Table 1 (pfmdr1 FR3
and FR4). The sequence of amplified DNA products was
determined using ABI PRISM 3730 Genetic Analyser
(Applied Biosystems, UK). Chromas software (Technely-
sium, Australia) was used to analyse the sequence
results. The DNA sequence was compared with refer-
ence sequence of the pfmdr1, pfdhfr and pfdhps portions
of the P. falciparum 3D7 clone using BLAST similarity
alignment (Washington University, USA). Appropriate
control DNA samples with known pfmdr1, pfdhfr and
Table 1 pfmdr1 PCR primer sequences and reaction conditions used in Fragments 3 and 4 amplification reactions
Gene Fragment Primer name Primer Sequence Codons PCR Cycling conditions
Fragment 3
Primary FR3 MDRF3N1 F 5’-GCATTTTATAATATGCATACTG-3’ 1034, 1042 94°C 3 min/[94°C 30 s-56°C 60 s 65°C 50 s]
MDRF3R1 R 5’-GGATTTCATAAAGTCATCAAC-3’ × 30 cycles
Nested FR3 MDRF3N2 F 5’-GGTTTAGAAGATTATTTCTGTA-3’ 65°C 5 min/15°C 5 min
MDRF3R1 R 5’-GCATTTTATAATATGCATACTG-3’
Fragment 4
Primary FR4 MDRF4N1 F 5’-CAAACCAATCTGGATCTGCAG-3’ 1246 94°C 3 min/[94°C 30 s-55°C 60 s-65°C 40 s]
MDRF4R1 R 5’-CAATGTTGCATCTTCTCTTCC-3’ × 30 cycles
Nested FR4 MDRF4N2 F 5’-GATCTGCAGAAGATTATACTG-3’ 65°C 5 min/15°C 5 min
MDRF4R1 R 5’-CAATGTTGCATCTTCTCTTCC-3’
Sequencing
FR3 MDRF3N2 F 5’-GGTTTAGAAGATTATTTCTGTA-3’ 96°C 1 min
MDRF3R1 R 5’-GCATTTTATAATATGCATACTG-3’ [96°C 30 s-50°C-60°C 4 min]
FR4 MDRF4N2 F 5’-GATCTGCAGAAGATTATACTG-3’ × 26 cycles
MDRF4R1 R 5’-CAATGTTGCATCTTCTCTTCC-3’
FR - Fragment F - forward R - Reverse
NB: Cycling conditions are the same for primary and nested PCRs.
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lected parasite isolates in every step of the protocol.
Results
Pfcrt polymorphisms
The pfcrt 72-76 haplotypes CVIET, CVMNK and
SVMNT were successfully identified in 70 DNA sam-
ples. Five (83%) of the six 2007 samples and 45 (70%) of
the sixty-four 1999 samples carried the CVIET haplo-
type. Only one (17%) of the 2007 samples carried the
wild type CVMNK haplotype while it occurred alone in
five (8%) of the 64 successfully amplified 1999 samples
(Table 2). Mixed haplotype infections (CVMNK/CVIET)
were found in 14 (22%) of the 1999 samples. No para-
sites carried mixed CVIET/CVMNK haplotypes among
the 2007 samples. The SVMNT haplotype was not
found in any of the isolates. These results suggest that
the prevalence of the CVIET haplotype remained high
between 1999 and 2007.
Pfmdr1 polymorphisms
Fifty samples from 1999 were successfully genotyped for
pfmdr1 at codons 86, 184, 1034, 1042 and 1246, as were
all 2007 samples. No mutations were found in codons
Table 2 Prevalence of pfcrt, pfmdr1, pfdhfr and pfdhps haplotypes in Swaziland: 1999 and 2007
Gene n Genotype/Haplotype Prevalence
1999 2007
pfcrt
Amino acids:
72 - 76
64 (1999) CVMNK wild-type 5 (8%) 1 (17%)
6 (2007) CVIET mutant 45 (70%) 5 (83%)
CVMNK/CVIET mixed 14 (22%) 0 (0%)
pfmdr1
Amino acids:
86,184,103, 1042, 1246.
51 (1999) 86N wild-type 12 (24%) 4 (67%)
6 (2007) 86Y mutant 37 (73%) 2 (33%)
86F mutant 2 (4%) 0 (0%)
50 (1999) 184Y wild-type 39 (78%) 2 (33%)
6 (2007) 184F mutant 11 (22%) 4 (67%)
51 (1999) 1246D wild-type 25 (51%) 6 (100%)
6 (2007) 1246Y mutant 25 (49%) 0 (0%)
50 (1999) NYD wild-type 2 (4%) 0 (0%)
6 (2007) NFD single-mutant 1 4 (8%) 4 (67%)
FYD single-mutant 2 2 (4%) 0 (0%)
NYY single-mutant 3 1 (2%) 0 (0%)
YYD single-mutant 4 15 (30%) 2 (33%)
YYY double-mutant 1 19 (38%) 0 (0%)
NFY double-mutant 2 4(8%) 0(0%)
YFD double-mutant 3 2(4%) 0 (0%)
YFY triple-mutant 1 (2%) 0 (0%)
pfdhfr
Amino acids:
50,51,59,108,164
34 (1999) CNCSI wild-type 3 (8%) 1 (17%)
6 (2007) CNCSI/CIRNI mixed 0 (0%) 1 (17%)
CIRNI triple-mutant 28 (82%) 3 (50%)
CIRNI/CIRNL mixed 0 (0%) 1 (17%)
CIRNI/CICNI mixed 3 (10%) 0 (0%)
Pfdhps
Amino acids:
436, 437, 540, 581,613.
27 (1999) SAKAA wild-type 25 (93%) 6 (100%)
6 (2007) SGEAA double-mutant 2 (7%) 0 (0%)
pfdhr & pfdhps 23 (1999) CNCSI/SAKAA 3 (13%) 1 (17%)
6 (2007) CIRNI/SAKAA 18 (78%) 5(83%)
CIRNI/SGEAA quintuple-mutant 2 (9%) 0 (0%)
NB: CIRNI/CIRNL, CIRNI/CICNI and CNCSI/CIRNI mixed haplotypes have been grouped into CIRNI for analysis of the prevalence of combined dhfr/dhps mutant
haplotypes. n = number of successfully genotyped samples. Mutant alleles are in bold for ease of identification.
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concentrated on codons 86, 184 and 1246 of pfmdr1.
Prevalence of the wild-type pfmdr1-86N allele was 24%
(n = 51) in 1999 and 67% in 2007 (n = 6). Unexpectedly,
a novel mutation showing substitution of asparagine (N)
with phenylalanine (F), rather than the common tyrosine
(Y) substitution, at the 86 position was observed in two
(4%) of the 1999 isolates from Swaziland. This mutation
has not been described in natural field isolates before,
but has been observed in two mefloquine-selected sub-
clones of the laboratory isolate W2mef [27]. Its origin
or implications are unknown. The mutant 184F and
1246Y alleles were found in 11/50 (22%) and 25/51
(49%) respectively among 1999 samples. The 184F allele
showed an increase in prevalence from 22% in 1999 to
67% in 2007. The 1246Y allele was not observed among
the 2007 isolates.
Nine different haplotypes were obtained from the ana-
lysis of the 86, 184 and 1246 codons (Table 2). The wild
type pfmdr1-NYD haplotype was observed in only two
(4%) of the 51 successfully sequenced 1999 samples but
was not observed in any of the 2007 samples. The pre-
valence of the single-mutant YYD haplotype remained
unchanged in the two years (33% and 30%, respectively).
Prevalence of the NFD haplotype was only 8% in 1999,
but was 67% in 2007. The double-mutant haplotype
YYY was found in many of the 1999 samples (19/50 =
38%) yet in none of the 2007 samples. This was also
true of the NFY haplotype, which was found in 4/50
(8%) of the 1999 samples but not in the 2007 samples
(Figure 1). Other haplotypes occurred with low fre-
quency in 1999 but were absent in 2007 and have not
been shown in the Figure. These are YFD( 4 % ) ,N Y Y
(2%), FYD (4%) and the triple-mutant haplotype YFY
(2%).
Pfdhfr polymorphisms
The 2007 isolates (n = 6) were all successfully geno-
typed for pfdhfr mutations at codons 16, 50, 51, 59, 108
and 164, while the DNA samples obtained by scraping
thick blood films from 1999 ran low: only 34 of the 73
isolates from 1999 (47%) were successfully genotyped.
The wild-type CNCSI haplotype was relatively uncom-
mon, occurring in 8% of isolates in 1999 and 17% of
isolates in 2007. Mixed infections, containing the triple-
mutant CIRNIa n dd o u b l e - m u t a n tC ICNI, were
observed in three (10%) of the 1999 isolates. The preva-
lence of the CIRNI triple-mutant haplotype of the dhfr
gene was 82% (28 of 34) in 1999, and 50% (3 of 6) in
2007, but a statistical test for evidence of a significant
reduction is not presented due to the low number of
isolates available for the 2007 analysis. Despite reports
of the pfdhfr I164L mutation in eastern Africa [28], this
allele was not found among Swaziland isolates. The pre-
valence of each pfdhfr haplotype identified is shown in
Table 2.
Pfdhps polymorphisms
Twenty-seven isolates from 1999 and all six isolates
from 2007 were successfully genotyped for dhps muta-
tions at the 431, 436, 437, 540, 581 and 613 codons. All
the 2007 isolates were wild-type ISAKAA while 93% of
the 1999 isolates carried this wild-type haplotype. The
remaining 7% carried the double-mutant ISGEAA
Figure 1 Prevalence of the five most common pfmdr1 haplotypes at codons 84, 184 and 1246 among Swaziland P. falciparum isolates
in 1999 (N = 50) and 2007 (N = 6).
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described from Nigerian isolates [23], was not observed.
Twenty-three samples were successfully genotyped for
both dhfr and dhps mutations. The prevalence of the
combined wild-type haplotype dhfr/dhps-CNCSI/
SAKAA was similar in 1999 (13%) and 2007 (17%). The
triple-mutant haplotype dhfr/dhps-CIRNI/ISAKAA also
remained highly prevalent at 78% (1999) and 83% (2007)
in the two years. Prevalence of the quintuple-mutation
CIRNI/ISGEAA was 9% (2 of 23) in 1999 and 0%
among the isolates collected in 2007. Other mutations
in dhfr including S108T and A16V were not found in
any of the isolates from Swaziland described herein.
Discussion
Malaria is still a major concern in Swaziland despite
recent reports of significant reduction of disease inci-
dence by more than 95% [29]. Selection of effective and
affordable anti-malarials for treatment and control
remain extremely important and complicated in this era
of emergence of P. falciparum parasites resistant to mul-
tiple anti-malarials. CQ failure in Swaziland was first
reported in 1987 [1]. More than twenty years later, Swa-
ziland retained CQ as a first-line anti-malarial for treat-
ing uncomplicated malaria. Although SP has not been
used as a first-line anti-malarial in Swaziland, it is still of
interest to determine whether parasites remain suscepti-
ble to the drug especially following reports of resistance
from neighbouring countries. SP is used as a second-line
anti-malarial for CQ resistant (CQR) parasites.
The high prevalence of the pfcrt CVIET haplotype,
which originated in CQR parasites from Southeast Asia
[30,31], and the absence of CQR haplotype SVMNT
(South American) among isolates examined in this study
is consistent with the earlier presumed spread of CQR
parasites from Southeast Asia to Africa via the Indian
subcontinent. Reports of SVMNT occurrence described
in isolated areas of East Africa are probably a result of
resistance to AQ or its metabolite desethyl-amodiaquine
(DEAQ) following use of AQ as monotherapy [32]. High
prevalence of 76T mutations both in 1999 and 2007
suggests that CQ resistance is widespread in Swaziland.
Studies have also shown that acquisition of 76T muta-
tions favours severity and multiplicity of malaria infec-
tion [33] and, together with pfmdr1 mutations, is
associated with life-threatening complications such as
severe anaemia (Hb<5 g/dl) in young children [34].
No published data are available on the in vivo efficacy
of CQ in Swaziland. Evidence of heavy over-prescription
is described here, in which only six of 252 patients trea-
ted for malaria in 2007 proved to be parasite positive by
both retrospective slide-reading and PCR. Previous stu-
dies elsewhere have shown that the 76T and 86Y muta-
tions occur among parasites surviving CQ treatment,
including those responsible for production of transmissi-
ble gametocytes [35,36]. In CQ-treated children, para-
sites with pfmdr1 86Y and pfcrt 76T are transmitted
more frequently than other genotypes and this mechan-
ism probably supports continued circulation of these
genotypes [37]. Further studies among malaria patients
in Swaziland are required to estimate any impact of
these mutations on treatment outcome. The pfmdr1-
1246Y allele, found at 49% prevalence among 1999
isolates, was absent among 2007 isolates, suggesting
withdrawal of CQ use may lead to further beneficial
changes in the parasite population in Swaziland.
The novel 86F mutation in pfmdr1 identified in two
s a m p l e sf r o mt h i ss t u d yh a sn o tp r e v i o u s l yb e e n
described in field-collected parasites. In the isolates
described here, the phenylalanine at position 86 is
encoded by the codon UUU, which has two base
changes from the wild-type asparagine codon AAU, but
only a single base-change from the common CQ-resis-
tance-associated tyrosine codon, UAU. The 86F allele is
therefore likely to have arisen from the 86Y form of
pfmdr1 by a single point mutation, rather than directly
from the wild-type 86N form, which would require a
minimum of two changes. This is consistent with in
vitro observations [27].
The absence of the wild-type pfmdr1-NYD haplotype
in 2007 and its low prevalence among 1999 isolates sug-
gest that CQ resistance had developed over a long time.
The high prevalence of the pfmdr1-NFDh a p l o t y p ei n
2007 and absence of the YYY haplotype is of interest, as
studies elsewhere in Africa have reported selection for
the NFD allele of pfmdr1 and loss of the YYY allele fol-
lowing treatment with artemether-lumefantrine (AL)
[12,13]. Since there is no history of AL use in Swaziland,
this pattern may be a result of the impact of drug policy
changes in neighbouring South Africa, KwaZulu-Natal
(KZN) and Mozambique. Swaziland is a very small
country and the influence of drug policies in Mozambi-
q u ea n dS o u t hA f r i c a( K Z N )c a n n o tb er u l e do u t .K Z N
introduced AL in 2001 while Mozambique introduced
artesunate-sulphadoxine/pyrimethamine (AS-SP) combi-
nation therapy in 2002 and artesunate/AQ in 2004.
Thus, deployment of AL in KZN and the introduction
of AS-SP treatment policy in Mozambique could have
influenced selection of 86N parasites through successful
transmission compared to their mutant counter-parts.
However, this phenomenon can only be confirmed
through analysis of a larger number of samples from
Swaziland. Transmission studies reported a four-fold
reduction in transmissibility to mosquitoes of the 86Y
allele compared to the 86N allele following addition of
artesunate to CQ [35]. The same study reported an
association between CQ monotherapy and increased
86Y transmissibility. Other studies have shown increased
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and halofantrine, (which are related to lumefantrine) if
they carried the 86N allele [10] or the 1034S/1042N/
1246D haplotype [38]. Therefore, the prevalence of NFD
haplotypes in Swaziland has to be closely monitored as
it could compromise the effectiveness of combinations
involving lumefantrine in the future. Unfortunately, data
o nt h ep r e v a l e n c eo fN FDa n dYYY haplotypes in KZN
following AL implementation in 2001 are not available.
Regional drug pressure, as well as prescription of SP
to CQ-resistant cases probably partly explains the high
prevalence of dhfr triple-mutant haplotypes (82%)
observed in 1999 in Swaziland. The prevalence of the
dhfr-CIRNI triple-mutant haplotype in Zone 1 in South-
ern Mozambique, the zone closest to Swaziland, was
47.5% in 1999 [39] which is lower than that observed in
Swaziland, suggesting only partial influence from
Mozambique, possibly because SP was in use in Swazi-
land as a second-line drug. In contrast, there was a high
prevalence of the triple-mutant haplotype at Masvold
Hospital in northern KZN [40] in 1999. The results
given here suggest that the prevalence of dhfr mutations
in Swaziland was high compared to that in neighbouring
countries. Thus, regional drug pressure alone may not
explain allele prevalence in Swaziland. SP drug pressure
in Swaziland may also have been further enhanced by
the use of other anti-folate compounds, such as the
combination antibiotic cotrimoxazole, which have cross-
resistance with SP. As HIV infection rates are high in
Swaziland, cotrimoxazole is commonly prescribed as
prophylaxis against opportunistic infections to HIV
patients [2], and may have contributed to persistence of
CIRNI triple-mutant malaria parasites in Swaziland.
The results presented here strongly support the recent
move to replace CQ with the highly efficacious artemisi-
nin-combination therapies (ACTs) in Swaziland. The
replacement of presumptive treatment with a quick,
simple and cheaper diagnostic method such as rapid
diagnostic tests (RDTs) to reduce inappropriate pre-
scription of drugs should reduce the cost of ACT drug
and further delay development of resistance. Deploy-
ment of AL in Swaziland is likely to further reduce pre-
valence of YYY haplotype but could increase the NFD
haplotype, and this may help preserve good AQ efficacy
[12,13,41], as will the recent withdrawal of AQ use in
neighbouring Mozambique. In the absence of the
pfmdr1 YYY haplotype, AQ shows in vivo and vitro effi-
cacy against parasite clones with the CVIET pfcrt haplo-
type [13,42]; parasites of this genotype are shown here
to be abundant in Swaziland.
Conclusion
This study is the first to document the presence and cir-
culation of CQR parasites in Swaziland. The high
prevalence of pfcrt-76T, pfmdr1-86Y, and pfmdr1-1246Y
among 1999 isolates suggests that the population of iso-
lates circulating in Swaziland has been selected by the
l o n gu s eo fC Q .T h e s ef i n d i n g st h u ss t r o n g l ys u p p o r t
the withdrawal of CQ as a first-line anti-malarial drug
for uncomplicated P. falciparum malaria, and replace-
ment with ACT. SP remains available for use in preg-
nant women, but the occurrence of the SGEAA
haplotype in Swaziland, previously associated with resis-
tance to sulphadoxine, suggests that SP use for treat-
ment of uncomplicated malaria might rapidly select for
these SP-resistant parasites. A weakness of this study is
the small number of isolates obtained during the health
facility survey in 2007. Genetic analysis of parasites from
larger surveys in Swaziland and neighbouring countries
is required for better understanding of the development
of anti-malarial drug resistance in this region.
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